FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 171.8208

Change

-1.09 (-0.63)%

Market Cap

N/A

Volume

6.46K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.64 (-0.41%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.50 (-0.68%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.94 (-0.83%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.36 (-0.40%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.27 (-1.07%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.13 (-0.34%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.92 (-0.94%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.36 (-1.21%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.68%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.20 (-0.68%)

USD 0.01B

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

N/A

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.71% 33% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.71% 29% F 45% F
Trailing 12 Months  
Capital Gain 17.74% 33% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.74% 33% F 49% F
Trailing 5 Years  
Capital Gain 30.64% 38% F 63% D
Dividend Return 1.68% 39% F 5% F
Total Return 32.33% 38% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 1.36% 24% F 44% F
Dividend Return 1.69% 24% F 34% F
Total Return 0.33% 37% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 12.29% 81% B- 72% C
Risk Adjusted Return 13.75% 33% F 35% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.